Rx-to-OTC Switches in the UK

Our UK team supports the reclassification of medicines from prescription-only (Rx) to over-the-counter status through the MHRA. The UK has a well-established Rx-to-OTC switch pathway with its own procedural requirements, evidence expectations, and advisory structures.

For the full description of our switch methodology (feasibility assessment, evidence development, dossier preparation, procedural strategy), see Regulatory Strategy & Operations.

UK Regulatory Landscape

The MHRA manages Rx-to-OTC reclassification through a structured process that involves scientific assessment, consultation, and in some cases advisory committee review.

MHRA reclassification procedure

Applications for reclassification are submitted to the MHRA with a supporting dossier demonstrating that the product can be used safely and effectively without medical supervision. The MHRA assesses the evidence, including the product’s safety profile, suitability of the indication for self-recognition, clarity of dosing, and adequacy of labelling for self-selection.

The MHRA may seek input from the Commission on Human Medicines (CHM) or its relevant expert advisory group. For some switches, a public consultation period may apply. The process timeline varies depending on complexity and whether advisory committee input is required.

Evidence expectations

The MHRA expects a comprehensive safety dataset from post-marketing experience, supported where necessary by specific evidence for the OTC context. This may include label comprehension studies (demonstrating that consumers understand the product information), self-selection studies (demonstrating that consumers can correctly identify whether the product is appropriate for them), and in some cases actual-use studies in real-world OTC settings.

Critically, data on UK usage is important for UK reclassification applications. International OTC history (e.g., existing OTC status in the US, Australia, or other markets) can support feasibility but the MHRA expects evidence relevant to the UK population and healthcare context.

OTC advertising framework

Once reclassified, the product moves from prescription advertising rules (HMR 2012 Part 14, ABPI Code) to OTC advertising rules (PAGB Consumer Code for public-facing, PAGB Professional Code for HCP-facing). This transition must be managed carefully: all prescription promotional materials must be withdrawn, and launch materials must comply with OTC codes from day one. For additional details see Promotional Materials & Compliance.

What We Handle Locally

Our UK team delivers the following within the UK Rx-to-OTC switch framework. For our full switch methodology (feasibility assessment, evidence development, dossier preparation, procedural strategy), see the central Regulatory Strategy & Operations page.

  • Conduct UK-specific feasibility assessments for proposed switches, evaluating the product’s suitability against MHRA reclassification criteria and UK OTC market context. Review UK post-marketing safety experience and prior MHRA reclassification precedent for similar products.
  • Prepare MHRA reclassification dossiers: clinical and safety data summaries, benefit-risk assessment, human factors evidence, labelling proposals, and self-selection justification, all framed for the MHRA’s assessment approach.
  • Manage MHRA engagement throughout the switch process: pre-submission discussions, formal application submission, responses to MHRA questions, and support during CHM or advisory committee review where applicable.
  • Coordinate evidence development programmes specific to UK requirements, including label comprehension studies and self-selection studies designed for the UK population and retail pharmacy context.
  • Plan and manage the promotional framework transition from Rx to OTC: withdrawal of prescription-only promotional materials, preparation of OTC-compliant launch materials under PAGB codes, and coordination with the copy approval team.
  • Support post-switch activities: MHRA-compliant OTC labelling, pharmacovigilance system adaptation for OTC reporting requirements, and ongoing OTC promotional compliance.

Our UK team has direct experience managing MHRA reclassification applications, with particular expertise in consumer health and the regulatory nuances of the UK OTC market.

Our UK Team

UK Rx-to-OTC switches are led by our regenold UK regulatory team, who have direct experience with MHRA reclassification applications, consumer health regulatory strategy, and the UK OTC market. The team works closely with our central regulatory strategy specialists on cross-market switch programmes and evidence development planning.

For the full team, see Our Teams.

Need support with your UK Rx-to-OTC switch?

Tell us about your product and we will outline how we can help.

Contact Us

Frequently Asked Questions (FAQ)

How long does an MHRA Rx-to-OTC switch take?

Timelines vary depending on the complexity of the evidence package and whether advisory committee review or public consultation is required. Simple switches with strong post-marketing safety data and clear self-care suitability can progress relatively quickly. Complex switches involving novel indications for self-care, narrow safety margins, or contested classifications may take significantly longer. Early MHRA engagement helps set realistic expectations.

Does prior OTC status in other countries help a UK switch?

International OTC history (US, Australia, Canada) provides supporting context and demonstrates that the product can be used safely in self-care settings. However, the MHRA expects evidence relevant to the UK specifically: UK post-marketing experience, UK-appropriate labelling, and where required, studies conducted with UK consumers. International data alone is typically insufficient.

What evidence do we need beyond standard safety data?

The MHRA may require label comprehension studies (showing consumers understand the PIL and packaging), self-selection studies (showing consumers correctly identify whether the product is suitable for their condition), and in some cases actual-use studies. Whether these are needed depends on the indication, the complexity of the dosing regimen, and the risk profile. We assess early whether additional studies are required and design them to meet MHRA expectations.

What happens to our promotional materials when a product switches?

All prescription-only promotional materials must be withdrawn at the point of reclassification. New OTC materials must comply with PAGB Consumer Code (public-facing) and PAGB Professional Code (HCP-facing). The promotional framework changes fundamentally: what you could say under the ABPI Code is not the same as what you can say under PAGB. We manage this transition, including preparing OTC-compliant launch materials and withdrawing Rx materials.